Supplemental material
OncoImmunology
Volume 8, 2019 - Issue 2
Original Research
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model
Lukasz KurykClinical Science, Targovax Oy, Helsinki, Finland;Department of Virology, National Institute of Public Health – National Institute of Hygiene, Warsaw, PolandCorrespondence[email protected]
http://orcid.org/0000-0003-1887-6361
http://orcid.org/0000-0003-1887-6361, & Related Research Data
Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
Source:
Elsevier BV
Discrimination between primary necrosis and apoptosis by necrostatin-1 in Annexin V-positive/propidium iodide-negative cells.
Source:
Elsevier BV
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology.
Source:
Taylor & Francis Group
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.
Source:
Springer Nature
Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.
Source:
American Association for Cancer Research (AACR)
Advances in Immunotherapy for Melanoma: A Comprehensive Review.
Source:
Hindawi Limited
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma.
Source:
Informa UK Limited
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer
Source:
Springer Science and Business Media LLC
Creation of “Humanized” Mice to Study Human Immunity
Source:
Wiley
Molecular characteristics of immunogenic cancer cell death.
Source:
Springer Science and Business Media LLC
Innate Immunity to Adenovirus
Source:
Mary Ann Liebert Inc
Humanized mice: novel model for studying mechanisms of human immune-based therapies
Source:
Springer Science and Business Media LLC
Chimeric Oncolytic Ad5/3 Virus Replicates and Lyses Ovarian Cancer Cells through Desmoglein‐2 Cell Entry Receptor
Source:
Wiley
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Source:
American Medical Association (AMA)
Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
Source:
American Society of Clinical Oncology (ASCO)
Immunogenic cell death in cancer and infectious disease
Source:
Springer Science and Business Media LLC
A potent form of tumor immunovirotherapy
Source:
Informa UK Limited
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Source:
Proceedings of the National Academy of Sciences
NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.
Source:
American Society of Hematology
TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
Source:
Informa UK Limited
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.
Source:
Public Library of Science (PLoS)
Immunogenic Cell Death in Cancer Therapy
Source:
Annual Reviews
Linking provided by
